IXICO plc IXICO selected to support Alzheimer's trial (5029Z)
21 Septiembre 2020 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 5029Z
IXICO plc
21 September 2020
IXICO plc
("IXICO" or the "Company")
IXICO selected to support Alzheimer's trial
Global Alzheimer's Platform Foundation selects IXICO for
innovative Bio-Hermes trial
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that is has been selected by
the Global Alzheimer's Platform Foundation(R) (GAP) to support
GAP's planned Bio-Hermes trial. IXICO will apply its expertise to
collect Positron Emission Tomography (PET) brain scans in
qualifying imaging centres participating in Bio-Hermes and provide
analysis of the scans.
Bio-Hermes' core purpose is development of a bio-sample database
to investigate biomarkers on a head-to-head basis in conjunction
with medical history elements. The Bio-Hermes trial will include
1,000 volunteers over the age of 60 screened for Preclinical
Alzheimer's Disease, Prodromal AD, or Mild Dementia AD.
Observational biomarker studies consistently suggest that amyloid
deposition and tau deposition in neurofibrillary tangles in the
brain may be the sentinel events in Alzheimer's Disease pathology.
In the Bio-Hermes trial, Avid Pharmaceuticals' Amyvid(TM) will be
used as the radioactive diagnostic agent to estimate
<BETA>-amyloid neuritic plaque density.
This contract does not have significant impact on management's
expectations of performance for the year, but will contribute to
the Company's already strong year end order book.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"We are delighted to be selected by GAP as their prime choice
for the analysis of PET scans in the Bio-Hermes trial. With a
reinvigorated level of interest in Alzheimer's disease, we are
excited about the prospects of long-term collaboration with our
colleagues at GAP who share our own commitment to reducing the
time, cost, and risk for Alzheimer's Disease trials. The support
provided by IXICO staff on Bio-Hermes is an important commercial
development in enhancing IXICO's market position in neuroimaging
for Alzheimer's Disease clinical trials."
John Dwyer, President of Global Alzheimer's Platform Foundation
(GAP), commented:
"Our collaboration with IXICO for neuroimaging and AI is a key
element of GAP's innovative Bio-Hermes trial, which is taking a
novel approach to provide digital and blood biomarker results for
comparison across cognitively normal and impaired individuals.
We've also committed to ground-breaking levels of minority
participation so that future treatment breakthroughs can benefit
everyone impacted by Alzheimer's."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd + 44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
Global Alzheimer's Platform Foundation Media 408-466-5952
Pamela Larkin or pamelalarkin@rational360.com
About the Global Alzheimer's Platform Foundation (GAP)
The Global Alzheimer's Platform Foundation (GAP) is a
patient-centric nonprofit dedicated to accelerating the delivery of
innovative therapies for neurological disorders by reducing the
duration and cost of clinical trials. Research centers across the
US and Canada are part of the growing GAP Network (GAP-Net). GAP
supports GAP-Net research centers by assisting with study start up
and recruitment activities, promoting diversity in research
studies, and offering national programs that champion brain health
and the citizen scientists who make research possible.
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKKKBNFBKKCCB
(END) Dow Jones Newswires
September 21, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024